Clinical Trials Logo

Clinical Trial Summary

This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients. The main questions it aims to answer are: - The LITT would increase the progression-free survival and overall survival of rHGG patients compared to other treatments. - The LITT is safe and applicable to rHGG patients Participants will be randomized to the intervention group (LITT) or control group at a ratio of 2:1. The intervention group patients will receive LITT. The control group will be treated with any other treatment. The primary outcome of this trial is progression-free survival. The estimated sample size is 135, 90 in the LITT group and 45 in the control group.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06161610
Study type Interventional
Source Beijing Tiantan Hospital
Contact Yunke Li, MD
Phone 0086-010-67088936
Email liyunke@sinovationmed.com
Status Recruiting
Phase N/A
Start date September 19, 2023
Completion date September 19, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03234595 - A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma Phase 1/Phase 2
Completed NCT02567539 - Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma N/A
Not yet recruiting NCT06126744 - Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 Phase 1
Recruiting NCT06305910 - CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults Phase 1
Recruiting NCT05698524 - A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma Phase 1
Completed NCT01172964 - A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Phase 1
Recruiting NCT05473923 - PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas Early Phase 1